{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-22-000123","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.845258+00:00","generated_at":"2026-06-22T02:08:37.509677+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xeris Biopharma Q3 product revenue $29.6M, record; raises cash guidance to $110-120M","bullets":["Net product revenue $29.6M, up 31% pro forma YoY; Gvoke $13.7M (+24%), Keveyis $13.4M, Recorlev $2.5M.","Full-year net product revenue guidance tightened to $105-110M; year-end cash guidance raised to $110-120M.","Net loss $21.8M ($0.16/share) for Q3; cash & investments $93.4M at Sept 30.","Positive Phase 1 topline for subcutaneous levothyroxine (XP-8121); FDA Type C meeting requested.","On track for $50M in synergies by year-end 2022 and cash flow breakeven by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-22-000123","json":"https://secwatch.observer/filing/0001867096-22-000123.json","markdown":"https://secwatch.observer/filing/0001867096-22-000123.md","text":"https://secwatch.observer/filing/0001867096-22-000123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000123/0001867096-22-000123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000123/xers-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:08:37.509677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}